Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-10-22 | Amended | $13,411,475 | $300,000 | Equity Only | 06c | SEC link |
| 2024-09-16 | New | $3,855,000 | $3,855,000 | Equity and Debt | 06b | SEC link |
| 2024-09-13 | Amended | $13,111,475 | $5,451,475 | Equity Only | 06c | SEC link |
| 2022-04-01 | Amended | $7,660,000 | $2,620,000 | Equity Only | 06c | SEC link |
| 2021-04-02 | Amended | $5,040,000 | $0 | Equity Only | 06c | SEC link |
| 2020-06-10 | Amended | $18,215,000 | $4,150,000 | Equity Only | 06c | SEC link |
| 2020-04-08 | New | $890,000 | $890,000 | Equity Only | 06c | SEC link |
| Name | Role |
|---|---|
| Hojabr Alimi | Director, Executive, Promoter |
| David Allie | Director |
| Tchekanova Banafsheh | Executive |
| Ronald Carli | Director |
| Sameer Harish | Executive |
| Kate Lewis | Director |
| Steven Solferino | Director |
| Jerry Stonemetz | Executive |
| William H. Watson | Director, Executive, Promoter |
| William Henry Watson Iii | Director, Executive, Promoter |
| Richard Zimmer | Executive |